Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C34H29ClN6O3 |
| Molecular Weight | 605.085 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)C1=C(NC(C)=C([C@H]1C2=CC=CC=C2Cl)C(=O)NC3=NC=CC=C3)C4=CC=C(C=C4)N5C(C)=NC6=CN=CC=C56
InChI
InChIKey=ODRYSCQFUGFOSU-SSEXGKCCSA-N
InChI=1S/C34H29ClN6O3/c1-4-44-34(43)31-30(24-9-5-6-10-25(24)35)29(33(42)40-28-11-7-8-17-37-28)20(2)38-32(31)22-12-14-23(15-13-22)41-21(3)39-26-19-36-18-16-27(26)41/h5-19,30,38H,4H2,1-3H3,(H,37,40,42)/t30-/m1/s1
| Molecular Formula | C34H29ClN6O3 |
| Molecular Weight | 605.085 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Modipafant is a dihydropyridine derivative patented by American multinational pharmaceutical corporation Pfizer Ltd. as platelet-activating factor antagonist for bronchoconstriction and asthma treatment. Platelet-activating factor, proposed as an important inflammatory mediator in asthma, reproduces several of the features of asthma, such as microvascular leakage, mucus secretion, bronchoconstriction, and possibly increased airway responsiveness. Unfortunately, in clinical trials, Modipafant failed to demonstrate superior efficacy compared to placebo.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:17:24 GMT 2025
by
admin
on
Mon Mar 31 18:17:24 GMT 2025
|
| Record UNII |
1DMI0E5023
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1327
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C073027
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
1DMI0E5023
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
DTXSID30153811
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
SUB09029MIG
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
6828
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
100000080350
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL2105829
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
122957-06-6
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
C90752
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY | |||
|
3047770
Created by
admin on Mon Mar 31 18:17:24 GMT 2025 , Edited by admin on Mon Mar 31 18:17:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
||
|
|
RACEMATE -> ENANTIOMER |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
